Investment and Company Research
Opportunity Research
MICROCAP HOT TOPICS

July 16, 2013

Preventive Measures For Prostate Cancer

Prostate cancer is a leading cause of death in men.  According to the American Cancer Society, in 2013 nearly 240,000 men will be diagnosed with the disease and nearly 30,000 will die from it in the U.S. alone.  Plus, one in six men will be diagnosed with prostate cancer at some point in their lives.  Finally, prostate cancer is the second leading cause of cancer related death in men, behind only lung cancer.  Clearly, treatment of this disease is a major concern and presents an opportunity for medical research and development.  Additionally, finding preventive products that health conscious men can routinely utilize will emerge as a way to fight prostate cancer and creates a large opportunity and market for companies such as Plandaí Biotechnology, Inc. (OTCQB – PLPL - $0.47 – Spec Buy).

For example, carotenoids are substances found in fruits that give them their respective bright colors, like tomatoes and oranges.  These nutrients are a key source of vitamin A and lycopene; a substance derived primarily tomatoes, which have been found to be beneficial in prevention of prostate cancer.  Data from a University of Illinois-Chicago study in 2010 demonstrated that men who consume a significant amount of lycopene reduced the risk of developing the disease by 35%.  Additionally, in a large epidemiologic study by Harvard University, researchers found that men who ate at least 10 servings a week of tomato-based foods reduced their risk for prostate cancer by 45%, while those who had four to seven servings lowered their risk by 20%.

To be certain, most men do not eat or have time to consume tomato based foods that provide the lycopene and vitamin A at the levels mentioned above.  As a result, dietary supplements will play a major role in preventive measures for prostate cancer.

Plandaí Phytofare Carotenoid Complex is a unique product that harnesses the beneficial effects of these nutrients due to the Company’s proprietary and advanced extraction process and ability to generate high absorption into the blood stream.  In fact, the product will offer one of the highest levels of lycopene found in a dietary supplement.  Looking at the Company’s line of offerings, we believe that this will be the third product in the Plandai arsenal that will be marketed and sold in 2014.  Among other approaches in marketing the Phytofare Carotenoid Complex, Plandaí will target the health conscious consumer seeking prevention of diseases like prostate cancer, which is likely a market reaching the hundreds of millions of dollars annually.

For more information, refer to our previous PLPL Reports, Updates and Hot Topics by visiting www.GoldmanResearch.com

Senior Analyst: Robert Goldman
Rob Goldman founded Goldman Small Cap Research in 2009 and has over 20 years of investment and company research experience as a senior research analyst and as a portfolio and mutual fund manager. During his tenure as a sell side analyst, Rob was a senior member of Piper Jaffray's Technology and Communications teams. Prior to joining Piper, Rob led Josephthal & Co.'s Washington-based Emerging Growth Research Group. In addition to his sell-side experience Rob served as Chief Investment Officer of a boutique investment management firm and Blue and White Investment Management, where he managed Small Cap Growth portfolios and The Blue and White Fund.

Analyst Certification
I, Robert Goldman, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report.

Disclaimer
This Opportunity Research Hot Topics article was prepared for informational purposes only. Goldman Small Cap Research, (a division of Two Triangle Consulting Group, LLC) produces research via two formats: Goldman Select Research and Goldman Opportunity Research. The Select product reflects the Firm’s internally generated stock ideas while the Opportunity product reflects sponsored research reports. It is important to note that while we may track performance separately, we utilize the same coverage criteria in determining coverage of all stocks in both research formats. While stocks in the Opportunity format may have a higher risk profile, they typically offer greater upside as well. Since May 2013, Goldman Small Cap Research has been compensated $500 per article by a third party and $4,000 for a research report service.

This article is the opinion of Goldman Small Cap Research and was written based upon publicly available information.  The Company has not endorsed or compensated Goldman Small Cap Research for this article. All information contained in this report was provided by the Company or derived from GSCR due diligence. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence. Analysts are compensated on a per report basis and not on the basis of his/her recommendations.

The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. Goldman Small Cap Research relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research report, update, article, or note is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed.

This publication does not take into account the investment objectives, financial situation, or particular needs of any particular person. This report does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA, the U.S. Securities and Exchange Commission or with any state securities regulatory authority.

ALL INFORMATION IN THIS REPORT IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.